FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068742492> ?p ?o ?g. }

• W2068742492 endingPage "65.e5" @default.
• W2068742492 startingPage "57" @default.
• W2068742492 abstract "Objective The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV. Design Multicenter, international, randomized, double-masked, active-treatment-controlled clinical trial. Participants Patients with predominantly classic, subfoveal CNV not previously treated with PDT or antiangiogenic drugs. Intervention Patients were randomized 1:1:1 to verteporfin PDT plus monthly sham intraocular injection or to sham verteporfin PDT plus monthly intravitreal ranibizumab (0.3 mg or 0.5 mg) injection. The need for PDT (active or sham) retreatment was evaluated every 3 months using fluorescein angiography (FA). Main Outcome Measures The primary, intent-to-treat efficacy analysis was at 12 months, with continued measurements to month 24. Key measures included the percentage losing <15 letters from baseline visual acuity (VA) score (month 12 primary efficacy outcome measure), percentage gaining ≥15 letters from baseline, and mean change over time in VA score and FA-assessed lesion characteristics. Adverse events were monitored. Results Of 423 patients (143 PDT, 140 each in the 2 ranibizumab groups), the majority (≥77% in each group) completed the 2-year study. Consistent with results at month 12, at month 24 the VA benefit from ranibizumab was statistically significant (P<0.0001 vs. PDT) and clinically meaningful: 89.9% to 90.0% of ranibizumab-treated patients had lost <15 letters from baseline (vs. 65.7% of PDT patients); 34% to 41.0% had gained ≥15 letters (vs. 6.3% of PDT group); and, on average, VA was improved from baseline by 8.1 to 10.7 letters (vs. a mean decline of 9.8 letters in PDT group). Changes in lesion anatomic characteristics on FA also favored ranibizumab (all comparisons P<0.0001 vs. PDT). Overall, there was no imbalance among groups in rates of serious ocular and nonocular adverse events. In the pooled ranibizumab groups, 3 of 277 (1.1%) patients developed presumed endophthalmitis in the study eye (rate per injection = 3/5921 [0.05%]). Conclusions In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Rates of serious adverse events were low. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. The 2-year, phase III trial designated Anti-vascular endothelial growth factor (VEGF) Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR) compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV. Multicenter, international, randomized, double-masked, active-treatment-controlled clinical trial. Patients with predominantly classic, subfoveal CNV not previously treated with PDT or antiangiogenic drugs. Patients were randomized 1:1:1 to verteporfin PDT plus monthly sham intraocular injection or to sham verteporfin PDT plus monthly intravitreal ranibizumab (0.3 mg or 0.5 mg) injection. The need for PDT (active or sham) retreatment was evaluated every 3 months using fluorescein angiography (FA). The primary, intent-to-treat efficacy analysis was at 12 months, with continued measurements to month 24. Key measures included the percentage losing <15 letters from baseline visual acuity (VA) score (month 12 primary efficacy outcome measure), percentage gaining ≥15 letters from baseline, and mean change over time in VA score and FA-assessed lesion characteristics. Adverse events were monitored. Of 423 patients (143 PDT, 140 each in the 2 ranibizumab groups), the majority (≥77% in each group) completed the 2-year study. Consistent with results at month 12, at month 24 the VA benefit from ranibizumab was statistically significant (P<0.0001 vs. PDT) and clinically meaningful: 89.9% to 90.0% of ranibizumab-treated patients had lost <15 letters from baseline (vs. 65.7% of PDT patients); 34% to 41.0% had gained ≥15 letters (vs. 6.3% of PDT group); and, on average, VA was improved from baseline by 8.1 to 10.7 letters (vs. a mean decline of 9.8 letters in PDT group). Changes in lesion anatomic characteristics on FA also favored ranibizumab (all comparisons P<0.0001 vs. PDT). Overall, there was no imbalance among groups in rates of serious ocular and nonocular adverse events. In the pooled ranibizumab groups, 3 of 277 (1.1%) patients developed presumed endophthalmitis in the study eye (rate per injection = 3/5921 [0.05%]). In this 2-year study, ranibizumab provided greater clinical benefit than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV. Rates of serious adverse events were low." @default.
• W2068742492 created "2016-06-24" @default.
• W2068742492 creator A5013644644 @default.
• W2068742492 creator A5028848967 @default.
• W2068742492 creator A5030449236 @default.
• W2068742492 creator A5052574764 @default.
• W2068742492 creator A5056477636 @default.
• W2068742492 creator A5059157551 @default.
• W2068742492 date "2009-01-01" @default.
• W2068742492 modified "2023-10-16" @default.
• W2068742492 title "Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study" @default.
• W2068742492 cites W1521704129 @default.
• W2068742492 cites W1696340081 @default.
• W2068742492 cites W2004351400 @default.
• W2068742492 cites W2019675142 @default.
• W2068742492 cites W2031734192 @default.
• W2068742492 cites W2085712747 @default.
• W2068742492 cites W2124415048 @default.
• W2068742492 cites W2132603123 @default.
• W2068742492 cites W2330813625 @default.
• W2068742492 cites W4239471829 @default.
• W2068742492 doi "https://doi.org/10.1016/j.ophtha.2008.10.018" @default.
• W2068742492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19118696" @default.
• W2068742492 hasPublicationYear "2009" @default.
• W2068742492 type Work @default.
• W2068742492 sameAs 2068742492 @default.
• W2068742492 citedByCount "1103" @default.
• W2068742492 countsByYear W20687424922012 @default.
• W2068742492 countsByYear W20687424922013 @default.
• W2068742492 countsByYear W20687424922014 @default.
• W2068742492 countsByYear W20687424922015 @default.
• W2068742492 countsByYear W20687424922016 @default.
• W2068742492 countsByYear W20687424922017 @default.
• W2068742492 countsByYear W20687424922018 @default.
• W2068742492 countsByYear W20687424922019 @default.
• W2068742492 countsByYear W20687424922020 @default.
• W2068742492 countsByYear W20687424922021 @default.
• W2068742492 countsByYear W20687424922022 @default.
• W2068742492 countsByYear W20687424922023 @default.
• W2068742492 crossrefType "journal-article" @default.
• W2068742492 hasAuthorship W2068742492A5013644644 @default.
• W2068742492 hasAuthorship W2068742492A5028848967 @default.
• W2068742492 hasAuthorship W2068742492A5030449236 @default.
• W2068742492 hasAuthorship W2068742492A5052574764 @default.
• W2068742492 hasAuthorship W2068742492A5056477636 @default.
• W2068742492 hasAuthorship W2068742492A5059157551 @default.
• W2068742492 hasConcept C118487528 @default.
• W2068742492 hasConcept C126322002 @default.
• W2068742492 hasConcept C141071460 @default.
• W2068742492 hasConcept C168563851 @default.
• W2068742492 hasConcept C178790620 @default.
• W2068742492 hasConcept C185592680 @default.
• W2068742492 hasConcept C197934379 @default.
• W2068742492 hasConcept C204243189 @default.
• W2068742492 hasConcept C2776403814 @default.
• W2068742492 hasConcept C2776694085 @default.
• W2068742492 hasConcept C2777802072 @default.
• W2068742492 hasConcept C2778257484 @default.
• W2068742492 hasConcept C2780248432 @default.
• W2068742492 hasConcept C2781100027 @default.
• W2068742492 hasConcept C2781148688 @default.
• W2068742492 hasConcept C2781323092 @default.
• W2068742492 hasConcept C2781359195 @default.
• W2068742492 hasConcept C71924100 @default.
• W2068742492 hasConceptScore W2068742492C118487528 @default.
• W2068742492 hasConceptScore W2068742492C126322002 @default.
• W2068742492 hasConceptScore W2068742492C141071460 @default.
• W2068742492 hasConceptScore W2068742492C168563851 @default.
• W2068742492 hasConceptScore W2068742492C178790620 @default.
• W2068742492 hasConceptScore W2068742492C185592680 @default.
• W2068742492 hasConceptScore W2068742492C197934379 @default.
• W2068742492 hasConceptScore W2068742492C204243189 @default.
• W2068742492 hasConceptScore W2068742492C2776403814 @default.
• W2068742492 hasConceptScore W2068742492C2776694085 @default.
• W2068742492 hasConceptScore W2068742492C2777802072 @default.
• W2068742492 hasConceptScore W2068742492C2778257484 @default.
• W2068742492 hasConceptScore W2068742492C2780248432 @default.
• W2068742492 hasConceptScore W2068742492C2781100027 @default.
• W2068742492 hasConceptScore W2068742492C2781148688 @default.
• W2068742492 hasConceptScore W2068742492C2781323092 @default.
• W2068742492 hasConceptScore W2068742492C2781359195 @default.
• W2068742492 hasConceptScore W2068742492C71924100 @default.
• W2068742492 hasFunder F4320332193 @default.
• W2068742492 hasFunder F4320332736 @default.
• W2068742492 hasIssue "1" @default.
• W2068742492 hasLocation W20687424921 @default.
• W2068742492 hasLocation W20687424922 @default.
• W2068742492 hasOpenAccess W2068742492 @default.
• W2068742492 hasPrimaryLocation W20687424921 @default.
• W2068742492 hasRelatedWork W2012546470 @default.
• W2068742492 hasRelatedWork W2031737722 @default.
• W2068742492 hasRelatedWork W2042956061 @default.
• W2068742492 hasRelatedWork W2079717275 @default.
• W2068742492 hasRelatedWork W2096935017 @default.
• W2068742492 hasRelatedWork W2319930158 @default.
• W2068742492 hasRelatedWork W2413182178 @default.
• W2068742492 hasRelatedWork W2577193304 @default.
• W2068742492 hasRelatedWork W4243304339 @default.

• next